Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia"
DOI: 10.1038/s41375-019-0611-9
Abstract: Hodgkin lymphoma (HL), accounting for ~10% of lymphomas diagnosed in the United States (1), have a largely favorable outcome (5-year survival 85%) that may be improved with anti-CD30-drug conjugates or checkpoint inhibitors (2, 3). However,… read more here.
Keywords: bcl bcl; targeting bcl; hodgkin lymphoma; hodgkin ... See more keywords
MiR-219-5p Inhibits the Growth and Metastasis of Malignant Melanoma by Targeting BCL-2
Sign Up to like & getrecommendations! Published in 2017 at "BioMed Research International"
DOI: 10.1155/2017/9032502
Abstract: Malignant melanoma is a very dangerous tumor which is resistant to conventional therapy. MicroRNA exerts a vital function in promoting or inhibiting tumor development. The research has investigated the expression and function of miR-219-5p in… read more here.
Keywords: melanoma; targeting bcl; malignant melanoma; mir 219 ... See more keywords
Targeting BCL-2 in B-cell lymphomas.
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2017-04-737338
Abstract: The B-cell leukemia/lymphoma-2 (BCL-2) family of proteins governs the intrinsic pathway of mitochondrial apoptosis. Dysregulation of BCL-2 has long been known to be a crucial part of the pathophysiology of B-cell lymphomas; however, several early… read more here.
Keywords: lymphoma; bcl cell; cell lymphomas; targeting bcl ... See more keywords